KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to -$2.9 billion.

  • Amgen's Cash from Financing Activities rose 2185.7% to -$2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 billion, marking a year-over-year decrease of 11012.56%. This contributed to the annual value of -$9.4 billion for FY2024, which is 14473.11% down from last year.
  • Per Amgen's latest filing, its Cash from Financing Activities stood at -$2.9 billion for Q3 2025, which was up 2185.7% from -$2.7 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's Cash from Financing Activities ranged from a high of $21.5 billion in Q1 2023 and a low of -$6.6 billion during Q4 2021
  • Moreover, its 5-year median value for Cash from Financing Activities was -$1.9 billion (2021), whereas its average is -$542.5 million.
  • As far as peak fluctuations go, Amgen's Cash from Financing Activities plummeted by 66338.58% in 2021, and later surged by 71209.45% in 2023.
  • Quarter analysis of 5 years shows Amgen's Cash from Financing Activities stood at -$6.6 billion in 2021, then soared by 84.0% to -$1.0 billion in 2022, then skyrocketed by 362.54% to $2.8 billion in 2023, then plummeted by 151.09% to -$1.4 billion in 2024, then plummeted by 102.77% to -$2.9 billion in 2025.
  • Its Cash from Financing Activities was -$2.9 billion in Q3 2025, compared to -$2.7 billion in Q2 2025 and -$4.1 billion in Q1 2025.